Kayayyaki

Niacin (nicotinic acid) a matsayin monotherapy na iya rage haɗarin cututtukan jijiyoyin jini, amma tsarin aikinsa ya kasance mai kawo rigima, kuma maiyuwa baya dogaro da tasirin gyare-gyaren lipid.Kwanan nan an nuna Niacin don inganta aikin endothelial da farfadowa na jijiyoyin jini, mai zaman kansa ba tare da gyara dyslipidemia ba, a cikin nau'in rodents na rauni na jijiyoyin jini da cututtuka na rayuwa.A matsayin mai yuwuwar biosynthetic precursor na NAD(+), niacin zai iya haifar da waɗannan fa'idodin jijiyoyin jini ta hanyar NAD(+) -dogara, sirtuin (SIRT) martanin sulhu.A madadin, niacin na iya yin aiki ta hanyar mai karɓar sa, GPR109A, don haɓaka aikin endothelial, kodayake ba a san sel na endothelial don bayyana wannan mai karɓa ba.Mun yi hasashe cewa niacin yana inganta aikin sel na endothelial kai tsaye yayin fallasa yanayin lipotoxic kuma an nemi sanin hanyoyin da za a iya amfani da su. in mun gwada ƙarancin maida hankali na niacin (10 μM), ko nicotinamide mononucleotide (NMN) (1 μM), precursor NAD (+) kai tsaye.Kodayake duka niacin da NMN sun inganta haɓakar bututun HMVEC yayin daɗaɗɗen palmitate, NMN kawai ya haɓaka aikin NAD(+) da aikin SIRT1.Mun kuma lura cewa HMVEC express GRP109A.Kunna wannan mai karɓa tare da ko dai acifran ko MK-1903 ya sake mayar da niacin-induced ingantawa a cikin HMVEC bututu, yayin da GPR109A siRNA ya rage tasirin niacin.Niacin, a cikin ƙananan ƙwayar cuta, yana inganta aikin HMVEC angiogenic a ƙarƙashin yanayin lipotoxic, mai yiwuwa mai zaman kansa na NAD( +) biosynthesis da kunna SIRT1, amma ta hanyar kunna mai karɓar niacin.